[go: up one dir, main page]

SE0004455D0 - Method for neuron regeneration in the central nervous system - Google Patents

Method for neuron regeneration in the central nervous system

Info

Publication number
SE0004455D0
SE0004455D0 SE0004455A SE0004455A SE0004455D0 SE 0004455 D0 SE0004455 D0 SE 0004455D0 SE 0004455 A SE0004455 A SE 0004455A SE 0004455 A SE0004455 A SE 0004455A SE 0004455 D0 SE0004455 D0 SE 0004455D0
Authority
SE
Sweden
Prior art keywords
substance
nervous system
central nervous
neuronal regeneration
ageing
Prior art date
Application number
SE0004455A
Other languages
English (en)
Inventor
Milos Pekny
Original Assignee
Milos Pekny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milos Pekny filed Critical Milos Pekny
Priority to SE0004455A priority Critical patent/SE0004455D0/sv
Publication of SE0004455D0 publication Critical patent/SE0004455D0/sv
Priority to AU2002223170A priority patent/AU2002223170A1/en
Priority to PCT/SE2001/002656 priority patent/WO2002043654A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0004455A 2000-12-01 2000-12-01 Method for neuron regeneration in the central nervous system SE0004455D0 (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0004455A SE0004455D0 (sv) 2000-12-01 2000-12-01 Method for neuron regeneration in the central nervous system
AU2002223170A AU2002223170A1 (en) 2000-12-01 2001-11-30 Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions
PCT/SE2001/002656 WO2002043654A2 (en) 2000-12-01 2001-11-30 Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0004455A SE0004455D0 (sv) 2000-12-01 2000-12-01 Method for neuron regeneration in the central nervous system

Publications (1)

Publication Number Publication Date
SE0004455D0 true SE0004455D0 (sv) 2000-12-01

Family

ID=20282072

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0004455A SE0004455D0 (sv) 2000-12-01 2000-12-01 Method for neuron regeneration in the central nervous system

Country Status (3)

Country Link
AU (1) AU2002223170A1 (sv)
SE (1) SE0004455D0 (sv)
WO (1) WO2002043654A2 (sv)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2759791C (en) 2009-04-30 2018-04-10 Midwestern University Novel therapeutic treatments using centhaquin
US10561704B2 (en) * 2013-07-08 2020-02-18 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist
US20150190377A1 (en) * 2014-01-06 2015-07-09 The Regents Of The University Of California, A California Corporation Neuronal regeneration
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用
JP2023520002A (ja) * 2020-03-31 2023-05-15 ▲ヌオ▼貝▲タイ▼医薬科技（上海）有限公司 細胞内タンパク質ミスフォールディング関連疾患およびリソソーム蓄積症におけるｐｉ４ｋ阻害物質の応用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1006798A4 (en) * 1996-09-05 2003-03-05 Massachusetts Inst Technology COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES
WO1998029547A1 (en) * 1996-12-31 1998-07-09 The Rockefeller University Modulators of radial glia-astrocyte differentiation and transformation, and diagnostic and therapeutic uses thereof
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration

Also Published As

Publication number Publication date
WO2002043654A2 (en) 2002-06-06
WO2002043654A8 (en) 2004-04-01
WO2002043654A3 (en) 2002-09-06
AU2002223170A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
WO2021026218A3 (en) Treatment of central nervous system disorders
Datta et al. The homeostatic regulation of REM sleep: a role for localized expression of brain-derived neurotrophic factor in the brainstem
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
DE59907752D1 (de) Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
ATE537872T1 (de) Gerät zur behandlung von neurologischen störungen mit chronisch adaptiver gehirn-stimulation in abhängigkeit von lokalen biopotentialen
EP1064000A4 (en) VITAMIN D AND ITS ANALOGS FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATION DISORDERS
ES2058592T3 (es) El uso de sustancias activas fisiologicamente para la fabricacion de medicamentos para enfermedades cerebrales y neuronales.
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
MX9304110A (es) Utilizacion de inhibidores del complemento para la preparacion de un medicamento destinado a la profilaxis y a la terapia de enfermedades intestinales y cutaneas inflamatorias asi como de purpura.
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004084839A3 (en) Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
SE0004455D0 (sv) Method for neuron regeneration in the central nervous system
WO2003057162A3 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
DE602004022284D1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid-neurotoxizität und mikrogliosis
Casale et al. Reduction of spastic hypertonia in patients with spinal cord injury: a double-blind comparison of intravenous orphenadrine citrate and placebo
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
WO2003030836A3 (en) Neuronal regeneration
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
WO2001082954A3 (en) Ceruloplasmin and uses thereof in neurodegenerative related conditions
JP2009532369A5 (sv)
RU2006147345A (ru) Способ лечения заболеваний, травм перефирической нервной системы, их последствий и последствий нарушения спинального мозгового кровообращения и спинальных травм
PT1235573E (pt) Associacao de riluzole e de gabapentina e sua utilizacao como medicamento no tratamento das doencas motoneuronais